NVO
Novo Nordisk A/S
NVO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OPCH
Option Care Health, Inc.
OPCH has the edge over NVO overall, supported by stronger valuation and lower modeled downside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OPCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
OPCH's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over OPCH in the historical PE scenario, which offers more potential upside but is not a forecast.
OPCH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $31.68 | — |
| Cheap | 20x | $27.79 | -12% |
| Current | 23x | $31.68 | — |
| Fair | 26x | $36.15 | +14% |
| Expensive | 38x | $52.50 | +66% |
Historical ranges are pointers, not guarantees.
OPCH's PE is in its cheap range at 23x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OPCH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
OPCH has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OPCH on earnings, with more consistent year-over-year improvement.
OPCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | +47% |
| Q3 2026 | $1.38 | +8.7% |
| Q2 2026 | $1.32 | +4.8% |
| Q1 2026 | $1.28 | +2.4% |
| Q4 2025 | $1.27 | +3.3% |
| Q3 2025 | $1.27 | +5.8% |
| Q2 2025 | $1.26 | +5% |
| Q1 2025 | $1.25 | -18% |
| Q4 2024 | $1.23 | -17% |
OPCH earned $1.38 per share over the past year, up 8.7% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OPCH on profitability, with a higher operating margin.
OPCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +4.1% |
| Q2 2026 | $1.4B | +1.9% |
| Q1 2026 | $1.4B | +1.3% |
| Q4 2025 | $1.5B | +16% |
| Q3 2025 | $1.4B | +12% |
| Q2 2025 | $1.4B | +15% |
| Q1 2025 | $1.3B | +16% |
| Q4 2024 | $1.3B | +12% |
OPCH's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6% | +0.1 points |
| Q2 2026 | 5.9% | +0.1 points |
| Q1 2026 | 5.4% | -0.6 points |
| Q4 2025 | 6.2% | -0.7 points |
| Q3 2025 | 5.9% | -0.8 points |
| Q2 2025 | 5.8% | -0.7 points |
| Q1 2025 | 5.9% | -0.1 points |
| Q4 2024 | 6.9% | -0.6 points |
OPCH's operating margin was 6% last quarter, about level with the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over OPCH on cash flow, with more consistent year-over-year improvement.
OPCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $108M | -17% |
| Q2 2026 | $172.5M | +112% |
| Q1 2026 | -$21.2M | -$4.6M |
| Q4 2025 | $22.2M | -14% |
| Q3 2025 | $130.2M | -14% |
| Q2 2025 | $81.2M | -56% |
| Q1 2025 | -$16.6M | +$58M |
| Q4 2024 | $25.8M | -17% |
OPCH generated $282M in free cash flow over the past year, up 28% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OPCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -3M shares |
| 1 year | -7.7% | -12.6M shares |
| 3 years | -17% | -30M shares |
| 5 years | -17% | -30.9M shares |
| Available history | -3.7% | -5.8M shares |
OPCH has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $95.1M |
| Q3 2025 | $62.5M |
| Q4 2024 | $92.6M |
| Q3 2024 | $42M |
| Q2 2024 | $78.1M |
| Q1 2024 | $40.1M |
| Q4 2023 | $75.2M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over OPCH on leverage, with a lower net debt burden relative to earnings.
OPCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 1.8x | Healthy |
OPCH's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OPCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.8 | Neutral |
| Stochastic | 98.1 | Overbought |
OPCH's weekly RSI is 70 (neutral) and its Stochastic is 98 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over OPCH on valuation relative to its sector.
OPCH PE vs Healthcare Sector
| Metric | OPCH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 32 | 29 | 3 pts above |
OPCH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OPCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.3 | 8.2% above |
| 20 week MA | $25.6 | 24% above |
| 50 week MA | $27.3 | 16% above |
| 100 week MA | $28.6 | 11% above |
| 200 week MA | $29.5 | 7.2% above |
OPCH has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
OPCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $15.6 | +5.1% |
| 2021 | $15.6 | $28.0 | +80% |
| 2022 | $28.0 | $30.2 | +8.1% |
| 2023 | $30.2 | $33.7 | +11% |
| 2024 | $33.7 | $22.9 | -32% |
| 2025 | $22.9 | $32.6 | +43% |
| 2026 YTD | $32.6 | $31.7 | -2.8% |
OPCH has the edge over NVO on returns for 2026, with the stronger performance.